Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors.

Abstract excerpt

Tyrosine-specific and other protein kinases are embedded in signaling networks critical for progression of tumors of all types. Hence, kinase inhibitors have nucleated a major arm of personalized cancer therapy. Unfortunately, almost all kinase inhibitors evoke resistance within a year or two, due to secondary mutations, and other alterations within the targeted kinase, or due to emergence of feedback regulatory...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Drug Resistance, Neoplasm
• Share to Feedback, Physiological
• Share to Mutation